Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002962 (
angina
)
21,142
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Toxicology and
carcinogenesis
studies of pentaerythritol tetranitrate (PETN), an organic nitrate used in explosives and as a therapeutic agent for
angina pectoris
, were conducted by administering diets containing PETN,NF (National Formulary Grade, a 1:4 mixture of PETN and lactose) to both sexes of F344 rats and B6C3F1 mice in 14-day, 13-week and 2-year studies. PETN was found to be essentially non-toxic in 14-day and 13-week studies at dietary concentrations as high as 10,000 ppm; the weight gain of female rats was lower than that of controls at 5000 and 10,000 ppm in the 13-week study. In the 13-week studies, one in ten high-dose female rats had an adenoma of the Zymbal gland and one in ten high-dose female mice had a hepatocellular adenoma. Dietary concentrations chosen for the 2-year studies were 5000 and 10,000 ppm for male rats and male and female mice, and 1240 and 2500 ppm for female rats. In the 2-year studies, there were no adverse effects on survival or body weight gains in either sex of rats or mice. No neoplastic or non-neoplastic lesions were considered to be related clearly to PETN administration. Neoplasms of the Zymbal gland occurred at low incidences in PETN-exposed groups of both sexes of rats in the 2-year study.
...
PMID:No evidence of toxicity or carcinogenicity of pentaerythritol tetranitrate given in the diet to F344 rats and B6C3F1 mice for up to two years. 225 87
Pentaerythritol tetranitrate (PETN, NF) is a drug used to prevent
angina pectoris
. PETN without a lactose stabilizer is used as an explosive. NTP Toxicology and
Carcinogenesis
studies were conducted by administering PETN, NF, to groups of F344/N rats and B6C3F1 mice of each sex once by gavage or in feed for 14 days, 13 or 14 weeks, or 2 years. The PETN component was greater than 99% pure. Genetic toxicology studies were conducted with Salmonella typhimurium and Chinese hamster ovary (CHO) cells. Fourteen-Day and Thirteen-Week Studies: All rats and mice lived to the end of the 14-day studies (dietary concentrations up to 50,000 ppm). Final mean body weights of dosed and control rats were comparable. The final mean body weight of female mice that received 50,000 ppm was 13% lower than that of controls. No clinical signs or toxic lesions were attributed to PETN, NF, administration. All rats and mice lived to the end of the 13-week (mice) and 14-week (rats) studies (dietary concentrations up to 50,000 ppm). Final mean body weights of dosed and control rats and mice were similar, although weight gains of female rats at 25,000 and 50,000 ppm were less than that of controls. The nitrite level in urine of rats and methemoglobin levels in whole blood of rats and mice were not affected by administration of PETN, NF. An adenoma of the Zymbal gland was seen in a female rat that received 50,000 ppm. A hepatocellular adenoma was seen in a female mouse that received 50,000 ppm. Based on these results and the NTP convention of limiting concentrations in 2-year feed studies to 5% of the diet, the 2-year studies were conducted by administering 0, 25,000 or 50,000 ppm PETN, NF, in feed for 104 weeks to groups of 50 male rats and for 103 weeks to groups of 49 or 50 mice of each sex. Groups of 50 female rats were given feed containing 0, 6,200, or 12,500 ppm PETN, NF, for 104 weeks. Body Weight and Survival in the Two-Year Studies: Mean body weights of high dose male rats were 2%-9% lower than those of controls throughout the study; body weights of all groups of female rats were similar. No significant differences in survival were observed between any groups of rats of either sex (male: control, 23/50; low dose, 29/50; high dose, 29/50; female: 33/50; 33/50; 31/50). Mean body weights of dosed and control mice were similar. The survival of both groups of dosed male mice was significantly greater than that of the controls (26/49; 38/50; 38/50). No significant differences in survival were observed between any groups of female mice (38/50; 30/50; 38/50). Nonneoplastic and Neoplastic Effects in the Two-Year Studies: No nonneoplastic lesions were attributed to PETN, NF, administration in rats or mice. Neoplasms of the Zymbal gland occurred in dosed male (control, 0/49; low dose, 3/45; high dose, 2/41) and dosed female (0/36; 1/37; 3/35) rats. The historical incidence of these neoplasms is 1% +/- 2% in untreated males and 0.6% +/- 1% in females. At no site was a significantly increased incidence of neoplasms observed in dosed male or female mice. Genetic Toxicology: PETN, NF, was not mutagenic in S. typhimurium strains TA98, TA100, TA1535, or TA1537 when tested with or without exogenous metabolic activation (S9). When tested for cytogenetic effects in cultured CHO cells, PETN, NF, induced sister chromatid exchanges (SCEs) in the presence and absence of metabolic activation; no induction of chromosomal aberrations was observed in CHO cells with or without activation. Audit: The data, documents, and pathology materials from the 2-year studies of PETN, NF, have been audited. The audit findings show that the conduct of the studies is documented adequately and support the data and results given in this Technical Report. Conclusions: Under the conditions of these 2-year feed studies, there was equivocal evidence of carcinogenic activity of PETN, NF, for male and female F344/N rats, based on a marginal increase in neoplasms of the Zymbal gland. Female rats might have tolerated a higher dose. There was no evidence of carcinogenic activity of PETN, NF, forher dose. There was no evidence of carcinogenic activity of PETN, NF, for male or female B6C3F1 mice fed diets containing 25,000, or 50,000 ppm for 2 years. No nonneoplastic lesions were attributed to PETN, NF, administration. Synonyms for PETN: 2,2-bis((nitrooxy)methyl)-1,3-propanediol dinitrate (ester); 2,2-bisdihydroxy-methyl-1,3-propanediol tetranitrate; niperyt; nitropentaerythritol; pentaerythrityl tetranitrate; penthrit Trade Names for PETN, NF: Angitet; Cardiacap; Dilcoran-80; Dipentrate; Hasethrol; Lentrat; Metranil; Mycardol; Neo-Corovas; Nitropenta; Nitropenton; Pentafin; Pentanitrine; Pentitrate; Pentral 80; Pentrite; Pentritol; Pentryate; Peridex; Pergitral; Peritrate; Perityl; Prevangor; Quintrate; Subicard; Terpate; Vasodiatol
...
PMID:NTP Toxicology and Carcinogenesis Studies of Pentaerythritol Tetranitrate (CAS No. 78-11-5) with 80% D-Lactose Monohydrate (PETN, NF) in F344/N Rats and B6C3F1 Mice (Feed Studies). 1269 39
Some Korean and oriental herbal prescriptions used for a syndrome expressed as chest paralysis and heartache are thought to be effective for
angina pectoris
. We investigated the effects of an oriental medicinal prescription, Geiji-Bokryung-Hwan (GBH) consisting of herbs of Cinnamomi Ramulus, Poria Cocos Hoelen (Pachymae Fungus), Moutan Cortex Radicis, Paeoniae Radix, and Persicae Semen, on growth-inhibitory activity and cancer chemopreventive activity in assays representing three major stages of
carcinogenesis
. The GBH was found to act as an potent inhibitor of cyclooxygenase (COX)-1 only but not as COX-2 inhibitor. Furthermore, the extract mediated anti-inflammatory effects and inhibited COX-associated hydroperoxidase functions (anti-promotion activity). Inhibitory effect of the GBH on the growth of cancer cell lines such as HepG2 cell and Hep3B cell was shown. These data suggest that GBH extracts merit investigation as a potential cancer chemopreventive agent in humans, especially in hepatological cancers.
...
PMID:Tumor initiation inhibition through inhibition COX-1 activity of a traditional Korean herbal prescription, Geiji-Bokryung-Hwan, in human hepatocarcinoma cells. 1623 57